Healthcare Industry News: Mylan
News Release - February 27, 2008
Mylan Announces Appointment of Jagdish Dore' as CEO and Managing Director of Matrix LaboratoriesPITTSBURGH, Feb. 27 (HSMN NewsFeed) -- Mylan Inc. (NYSE: MYL ) today announced the appointment of Jagdish Viswanath Dore' as CEO and Managing Director of Matrix Laboratories Limited. Mr. Dore' will assume the responsibilities of Rajiv Malik who became Executive Vice President and Head of Global Technical Operations for Mylan in October 2007 and has been serving as interim CEO for Matrix, a majority-owned subsidiary of Mylan. Mr. Malik will relocate to the United States in connection with his employment by Mylan.
Mr. Dore' joins Matrix after a distinguished 29 year career with Sandoz most recently as Managing Director and India Country Head. In this role, Mr. Dore' was responsible for all of Sandoz's operations in India including global development and manufacturing; local and export sales; day-to-day operations; and technical operations in the Asia Pacific region. He was previously responsible for business operations in the Asia Pacific cluster and involved in the startup of Novartis Enterprises Private Limited (now Sandoz), Novartis Consumer Health India Private Limited and Master Builders Technology India Private Limited, India.
Matrix Chairman and Mylan Vice Chairman and CEO Robert J. Coury said: "Jagdish's impressive industry reputation is well known, and I believe he will be a huge asset to Matrix as it continues to expand its integral role in support of Mylan's global platform. I have every confidence that Jagdish will ensure that Matrix continues its strong growth and supports Mylan in becoming the world's leading, fully-integrated generic pharmaceuticals company."
N. Prasad, Matrix's Vice Chairman, commented, "I have known Jagdish for some time, and I am absolutely delighted that he will be assuming Rajiv's role as CEO of Matrix. During his tenure at Sandoz, Jagdish was responsible for managing the company's 1,800 employees based in India along with developing a rapidly growing business across the Asia Pacific region. He brings a great deal of experience on a strategic and operational level that will be invaluable to Matrix as it strengthens its leadership in active pharmaceutical ingredients (API), further develops its finished dosage form (FDF) capabilities and continues to grow its antiretroviral (ARV) business."
Mr. Dore' said: "Matrix is an established, highly respected and high- quality company in the pharmaceuticals industry both in India and world-wide. It is only enhanced by being part of Mylan. I look forward to leading Matrix into the next phase of its growth and working with the Mylan and Matrix senior management teams to further align our organizations and leverage the opportunities available to us in the global generics market."
Mr. Dore' earned a Bachelor of Technology degree from the Indian Institute of Technology, Chennai, and a postgraduate degree in business management from the Xavier Institute in Jamshedpur specializing in marketing.
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit www.Mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid(R) SoluTab Delayed-Release Orally Disintegrating Tablets